Antiangiogenic therapy: Not just for cancer anymore?

Hepatology

Volumn 49, Issue 4, 2009, Pages 1066-1068

  Shah, Vijay H ^a   Bruix, Jordi ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLEEDING; COLLATERAL CIRCULATION; DRUG DOSE REDUCTION; DRUG SAFETY; EDITORIAL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; VARIX BLEEDING; VASA VASORUM; ANIMAL; NOTE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; PYRIDINES;

EID: 65449167923     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22872     Document Type: Editorial

References (13)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: 378-390.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
4. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. HEPATOLOGY2007; 46:1919-1926.
5. Semela D, Das A, Langer DA, Kang N, Leof E, Shah VH. Platelet-derived growth factor signaling through ephrin-B2 regulates hepatic vascular structure and function Gastroenterology 2007;135:671-679.
6. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: A new function for the liver-specific pericyte? HEPATOLOGY2007; 45:817-825.
7. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2008; doi: 10.1016/ j.jhep.2008.12.011.
8. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008;135:1729-1738.
9. Novo E, Cannito S, Zamara E, Valfre di Bonzo L, Caligiuri A, Cravanzola C, et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007;170:1942-1953.
10. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. HEPATOLOGY2009; doi:10.1002/hep.22758.
11. Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: The need for randomized phase II trials. J Clin Oncol 2009; doi: 10.1200/JCO.2008.19.1973.
12. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-2998.
13. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-344.